Shanghai Fosun Pharmaceutical (600196) Q1 2025 earnings summary

Executive summary

• Revenue for Q1 2025 was RMB 9,420 million (¥9.42 billion), down 7.26% year-over-year, mainly due to VBP renewals and centralized drug procurement impacts.

• Net profit attributable to shareholders rose 25.42% year-over-year to RMB 765 million (¥764.76 million), driven by asset sales and fair value changes.

• Adjusted net profit after one-off gain was RMB 410 million (¥410.42 million), down 32.56% year-over-year.

• Operating cash flow increased 15.08% year-over-year to RMB 1.06 billion, supported by enhanced operational efficiency and supply chain management.

• Strategic focus on innovative drugs, high-value devices, and international expansion, with two new drug approvals and expanded licensing agreements.

Financial highlights

• Gross margin decreased to 47.8% from 50.0% year-over-year, reflecting lower revenue and VBP impact.

• R&D expense was RMB 737 million, down 11.10% year-over-year, with stable R&D intensity and focus on key pipelines.

• Selling and distribution expenses fell to RMB 2,126 million, with improved management and resource allocation.

• Cash and bank balances at RMB 13,716 million; net assets attributable to shareholders at RMB 47,924 million.

• Basic and diluted EPS was ¥0.29, up 26.09% year-over-year.

Outlook and guidance

• Continued focus on innovative drugs, high-value devices, and international expansion, with new product launches and licensing deals.

• Ongoing optimization of asset structure and strict capital expenditure control to improve free cash flow.

• Strategic transformation to drive long-term growth despite short-term revenue pressure from VBP and centralized procurement.